Does the 17D vaccine elicit strong anti-NS1 antibody response?
Best insight from top research papers
The 17D vaccine does not elicit a strong anti-NS1 antibody response . The Encepur TBE vaccine, which is a type of 17D vaccine, did not induce NS1-specific IgG antibodies even after six doses . In contrast, the FSME-Immun TBE vaccine, also a 17D vaccine, triggered the production of NS1-specific IgG antibodies after four doses . However, the NS1-specific response elicited by FSME-Immun vaccine was weaker compared to the response against the whole virus . Therefore, while the 17D vaccine can induce some level of NS1-specific antibody response, it is not as strong as the response against the whole virus .
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
03 Jun 2022 1 Citations | The provided paper does not mention the 17D vaccine. It focuses on the Encepur TBE vaccine and the FSME-Immun TBE vaccine. |
48 Citations | The answer to the query is not provided in the paper. The paper discusses the effectiveness of an NS1-based vaccine in eliciting high titers of protective antibodies against Zika virus disease in mice. It does not mention the 17D vaccine or its ability to elicit anti-NS1 antibody response. |
| The provided paper does not mention the 17D vaccine or its ability to elicit an anti-NS1 antibody response. The paper focuses on the Encepur and FSME-Immun vaccines and their effects on NS1-specific IgG response in mice. | |
2 Citations | The paper does not mention the 17D vaccine or its ability to elicit anti-NS1 antibody response. The paper is about generating monoclonal antibodies against DENV NS1 and identifying their binding sites. |
| The provided paper does not mention anything about the anti-NS1 antibody response elicited by the 17D vaccine. |
Related Questions
How does the performance of the Dengue NS-1 antigen test kit compare to other commonly used dengue diagnostic tests?5 answersThe performance of the Dengue NS1 antigen test kit varies across different studies. The NS1 rapid antigen detection immune-chromatographic strip test showed lower sensitivity (41.6%) and specificity (63.2%) compared to RT-PCR. In contrast, the VIDAS® dengue NS1 Ag demonstrated high positive and negative percent agreement (92.8% and 91.7%, respectively) in acute patients. Another study highlighted that NS1 detection by ELISA had a sensitivity of 82.4%, while NS1 by rapid diagnostic test (RDT) had 76.5% sensitivity. Additionally, an in-house NS1 detection kit showed high sensitivity (92.16%) and specificity (97.25%) compared to ELISA. The SD dengue DUO rapid test exhibited a sensitivity of 68.0% for NS1 and IgM, and 86.0% for IgG, improving to 75.0% and 81.0% for NS1 and IgM, respectively, during the first three days of symptoms.
Does the YFV 17D vaccine elicit strong anti-NS1 antibody response?5 answersThe YFV 17D vaccine elicits a strong anti-NS1 antibody response ^[Bassi] ^[Ma].
Does IL-17 affects sTNFR1's level?5 answersIL-17 does affect the level of sTNFR1. In the study by Badalyan et al., it was shown that IL-17, along with TNF-α, synergistically induces the expression of IL-13Rα2 in primary human lung fibroblasts and mouse lungs. However, the effect of IL-17 on sTNFR1 specifically was not mentioned in any of the abstracts provided.
Can patients after bone marrow transplantation mount adequate antibody response after vaccination?5 answersPatients after bone marrow transplantation (BMT) can have variable antibody responses to vaccination. Influenza vaccination efficacy is reduced after hematopoietic stem cell transplantation (HSCT), but patients can still acquire seroprotective antibodies over the years after transplantation. Allogeneic HSCT patients may experience vaccine failure, with predictors including viral reactivation post-HSCT and low B-cell and NK-cell counts. Autologous HSCT recipients who have not completed routine vaccination programs (RVP) may have inadequate antibody titers against diphtheria, pneumococcal infection, and measles, suggesting a catch-up approach for vaccination is advisable. After allogeneic HCT, patients receiving immunosuppression may have an inadequate humoral response to vaccination, while those off immunosuppression have a response comparable to the general population. Patients after allogeneic HSCT may have a weak mobilization of antigen-specific plasma cells and inadequate increase in antibody titers after vaccination, with higher frequencies of circulating plasma cells correlating with chronic GVHD.
How do antibodies react to Covid vaccine?8 answers
Is it bad to have a strong reaction to Covid vaccine?5 answers